New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
08:22 EDTCPRXCatalyst Pharmaceutical completes patient enrollment for Firdapse Phase 3 trial
Catalyst Pharmaceutical Partners announced that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. Based on the enrollment and randomization success metrics achieved to date, the Company believes that it has enrolled a sufficient number of LEMS patients to ensure that 36 patients will be randomized into the double-blind, placebo-controlled, discontinuation portion of the trial.
News For CPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CPRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use